Study #2022-0881
FORAGER-1: a phase 1, open-label, multicenter study of LOXO-435 (LY3866288) in locally advanced or metastatic solid tumors including urothelial cancer with FGFR3 alterations
MD Anderson Study Status
Enrolling
Treatment Agent
LOXO-435, Pembrolizumab, enfortumab vedotin
Description
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Study phase:
Phase I
Physician name:
Arlene Siefker-Radtke
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.